Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Amortizatization of Intangibles (2019 - 2025)

Crinetics Pharmaceuticals (CRNX) has 7 years of Amortizatization of Intangibles data on record, last reported at $13.1 million in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 269.1% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $15.4 million, up 407.07%, while the annual FY2025 figure was $15.4 million, 407.07% up from the prior year.
  • Amortizatization of Intangibles reached $13.1 million in Q4 2025 per CRNX's latest filing, up from -$6.7 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $13.1 million in Q4 2025 and bottomed at -$7.7 million in Q4 2024.
  • Average Amortizatization of Intangibles over 5 years is $1.2 million, with a median of $440500.0 recorded in 2022.
  • Peak YoY movement for Amortizatization of Intangibles: soared 921.08% in 2023, then crashed 315.57% in 2024.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$186000.0 in 2021, then soared by 288.71% to $351000.0 in 2022, then skyrocketed by 921.08% to $3.6 million in 2023, then plummeted by 315.57% to -$7.7 million in 2024, then skyrocketed by 269.1% to $13.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $13.1 million in Q4 2025, -$6.7 million in Q3 2025, and $4.7 million in Q2 2025.